PNPLA6
Basic information
Region (hg38): 19:7534004-7561764
Links
Phenotypes
GenCC
Source:
- Laurence-Moon syndrome (Supportive), mode of inheritance: AR
- cerebellar ataxia-hypogonadism syndrome (Supportive), mode of inheritance: AR
- ataxia-hypogonadism-choroidal dystrophy syndrome (Supportive), mode of inheritance: AR
- trichomegaly-retina pigmentary degeneration-dwarfism syndrome (Supportive), mode of inheritance: AR
- hereditary spastic paraplegia 39 (Supportive), mode of inheritance: AR
- ataxia-hypogonadism-choroidal dystrophy syndrome (Definitive), mode of inheritance: AR
- hereditary spastic paraplegia 39 (Strong), mode of inheritance: AR
- retinal dystrophy-ataxia-pituitary hormone abnormality-hypogonadism syndrome (Definitive), mode of inheritance: AR
- PNPLA6-related spastic paraplegia with or without ataxia (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Boucher-Neuhauser syndrome; Laurence-Moon syndrome; Oliver-McFarlane syndrome | AR | Endocrine | For Boucher-Neuhauser syndrome, Laurence-Moon syndrome, and Oliver-McFarlane syndrome, management related to hypogonadotropic hyponadism, surveillance in adolescence related to sexual maturation is indicated, as is monitoring of bone mineral density in order to allow early detection and treatment of disease; In order to induce and maintain secondary sex characteristics, gradually increasing doses of gonadal steroids (females: estrogen/progestin; males: testosterone/hCG) may be beneficial; Related to fertility in Boucher-Neuhaser syndrome, endocrinologic therapy (females: recombinant hCG or pulsatile GnRH therapy; males: hCG/HMG/recombinant FSH or pulsatile GnRH therapy) may be effective, though IVF may be required; For Oliver-McFarlane syndrome, recognition of other pituitary deficiencies (such as thyroid hormone deficiency) may allow prompt diagnosis and medical management | Craniofacial; Genitourinary; Endocrine; Musculoskeletal; Neurologic; Ophthalmologic | 8053762; 18313024; 24355708; 25033069; 25480986 |
ClinVar
This is a list of variants' phenotypes submitted to
- Hereditary_spastic_paraplegia_39 (1156 variants)
- not_provided (203 variants)
- Inborn_genetic_diseases (115 variants)
- not_specified (51 variants)
- Hereditary_spastic_paraplegia (49 variants)
- Ataxia-hypogonadism-choroidal_dystrophy_syndrome (31 variants)
- PNPLA6-related_disorder (30 variants)
- Laurence-Moon_syndrome (17 variants)
- Trichomegaly-retina_pigmentary_degeneration-dwarfism_syndrome (16 variants)
- Retinal_dystrophy (9 variants)
- Spastic_ataxia (4 variants)
- Mucolipidosis_type_IV (3 variants)
- Spastic_Paraplegia,_Recessive (3 variants)
- Cerebellar_ataxia-hypogonadism_syndrome (3 variants)
- Dysarthria (3 variants)
- Amyotrophic_lateral_sclerosis (2 variants)
- Rod-cone_dystrophy (2 variants)
- Cerebellar_ataxia (2 variants)
- Hypogonadotropic_hypogonadism_7_with_or_without_anosmia (2 variants)
- Gait_ataxia (2 variants)
- Cerebellar_atrophy (2 variants)
- Peripheral_neuropathy (1 variants)
- Marfanoid_habitus_and_intellectual_disability (1 variants)
- Amenorrhea (1 variants)
- Hypogonadism_with_anosmia (1 variants)
- HP:0000365 (1 variants)
- Optic_atrophy (1 variants)
- Peripheral_precocious_puberty (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PNPLA6 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001166114.2. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 25 | 347 | 376 | |||
missense | 13 | 32 | 441 | 18 | 505 | |
nonsense | 18 | 23 | ||||
start loss | 0 | |||||
frameshift | 28 | 42 | ||||
splice donor/acceptor (+/-2bp) | 17 | 26 | ||||
Total | 64 | 60 | 478 | 365 | 5 |
Highest pathogenic variant AF is 0.000164842
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PNPLA6 | protein_coding | protein_coding | ENST00000414982 | 33 | 27761 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.94e-13 | 1.00 | 125631 | 0 | 117 | 125748 | 0.000465 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.35 | 529 | 896 | 0.591 | 0.0000669 | 8701 |
Missense in Polyphen | 101 | 264.78 | 0.38146 | 2518 | ||
Synonymous | -0.146 | 401 | 397 | 1.01 | 0.0000307 | 2942 |
Loss of Function | 4.00 | 33 | 68.8 | 0.480 | 0.00000390 | 725 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000509 | 0.000507 |
Ashkenazi Jewish | 0.000100 | 0.0000992 |
East Asian | 0.000384 | 0.000381 |
Finnish | 0.000374 | 0.000370 |
European (Non-Finnish) | 0.000651 | 0.000642 |
Middle Eastern | 0.000384 | 0.000381 |
South Asian | 0.000425 | 0.000425 |
Other | 0.000327 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Phospholipase B that deacylates intracellular phosphatidylcholine (PtdCho), generating glycerophosphocholine (GroPtdCho). This deacylation occurs at both sn-2 and sn-1 positions of PtdCho. Its specific chemical modification by certain organophosphorus (OP) compounds leads to distal axonopathy. {ECO:0000269|PubMed:15044461, ECO:0000269|PubMed:1666291}.;
- Disease
- DISEASE: Spastic paraplegia 39, autosomal recessive (SPG39) [MIM:612020]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG39 is associated with a motor axonopathy affecting upper and lower limbs and resulting in progressive wasting of distal upper and lower extremity muscles. {ECO:0000269|PubMed:18313024, ECO:0000269|PubMed:24355708}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Boucher-Neuhauser syndrome (BNHS) [MIM:215470]: An autosomal recessive disorder characterized by spinocerebellar ataxia, hypogonadotropic hypogonadism, and visual impairment due to chorioretinal dystrophy. The age at onset is variable, but most patients develop 1 or more symptoms in the first decade of life. Chorioretinal dystrophy may not always be present. {ECO:0000269|PubMed:24355708, ECO:0000269|PubMed:25033069}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Laurence-Moon syndrome (LNMS) [MIM:245800]: An autosomal recessive syndrome characterized by progressive spinocerebellar degeneration, spastic paraplegia, mental retardation, hypogonadism, dwarfism, and chorioretinopathy. Trichomegaly is absent. {ECO:0000269|PubMed:25480986}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Oliver-McFarlane syndrome (OMCS) [MIM:275400]: A rare autosomal recessive, congenital syndrome characterized by trichomegaly, severe chorioretinal atrophy and multiple pituitary hormone deficiencies. It results in intellectual impairment and dwarfism, if untreated. Clinical features include hypogonadotropic hypogonadism during puberty, pigmentary retinal degeneration, ataxia, spastic paraplegia, and peripheral neuropathy. {ECO:0000269|PubMed:25480986}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Glycerophospholipid metabolism - Homo sapiens (human);Metabolism of lipids;Metabolism;Glycerophospholipid catabolism;PI Metabolism;Phospholipid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.159
Intolerance Scores
- loftool
- 0.822
- rvis_EVS
- -1.14
- rvis_percentile_EVS
- 6.38
Haploinsufficiency Scores
- pHI
- 0.103
- hipred
- Y
- hipred_score
- 0.563
- ghis
- 0.509
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.546
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pnpla6
- Phenotype
- homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); embryo phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Zebrafish Information Network
- Gene name
- pnpla6
- Affected structure
- motor neuron
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- phosphatidylcholine metabolic process;glycerophospholipid catabolic process
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum membrane;membrane;integral component of membrane
- Molecular function
- lysophospholipase activity